SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting

Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872), announced today that an abstract on updated safety and efficacy outcomes of vodobatinib in refractory chronic myeloid leukemia (CML) subjects has been selected for oral presentation at the 63rd American Society of Hematology (ASH) Annual Meeting. The Phase 1 study outcomes will be presented by Prof. Jorge Cortes, the Principal Investigator for the study, on Saturday, 11 Dec 2021. Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of vodobatinib for the treatment of heavily pre-treated CML.

Vodobatinib is a novel, third generation, selective BCR-Abl1 tyrosine kinase inhibitor (TKI) developed by SPARC for the treatment of patients with CML who are resistant or intolerant to ≥3 TKIs or ineligible for TKIs. Majority of the CML patients enrolled in the Phase 1 study had failed ≥3 TKIs. Similar anti-leukemic activity (major cytogenetic response ≥60%) was observed in CML-CP patients with or without prior ponatinib treatment. The current abstract provides longer term safety and efficacy updates to vodobatinib therapy. Vodobatinib has been granted Orphan Drug Designation for treatment of CML patients by USFDA and EMA. A Phase 2 study has been initiated and is recruiting globally.

"We look forward to presenting the data from the vodobatinib study at the 2021 ASH annual meeting. We are very encouraged by the anti-leukemic activity and safety profile of vodobatinib," said Siu-Long Yao, Executive Vice President, Clinical Development and Operations of SPARC.

Shares of Sun Pharma Advanced Research Company Limited was last trading in BSE at Rs. 257.80 as compared to the previous close of Rs. 248.80. The total number of shares traded during the day was 53601 in over 2144 trades.

The stock hit an intraday high of Rs. 259.25 and intraday low of 248.65. The net turnover during the day was Rs. 13608953.00.

Source : Equity Bulls

Keywords

SunPharmaAdvancedResearchCompany INE232I01014 SPARC Vodobatinib CML ASH ClinicalData